SCOPUS 정보 검색 플랫폼

Journal of the National Cancer Institute

Volumn 93, Issue 15, 2001, Pages 1120-1121

Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of herceptin response?

(1) Thor, A a

a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; CLINICAL LABORATORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; METASTASIS; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0035422149 PISSN: 00278874 EISSN: None Source Type: Journal
DOI: 10.1093/jnci/93.15.1120 Document Type: Editorial

Times cited : (26)

References (11)

1
- 0034468132
- Tyrosine kinase signalling in breast cancer. ErbB family receptor tyrosine kinases
- (2000) Breast Cancer Res , vol.2 , pp. 176-183
- Stern, D.F.¹

2
- 0032538050
- erbB-2. p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
- (1998) J Natl Cancer Inst , vol.90 , pp. 1346-1360
- Thor, A.D.¹ Berry, D.A.² Budman, D.R.³ Muss, H.B.⁴ Kute, T.⁵ Henderson, I.C.⁶

3
- 0032538006
- Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?
- (1998) J Natl Cancer Inst , vol.90 , pp. 1320-1321
- Clark, G.M.¹

4
- 0032538040
- erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
- (1998) J Natl Cancer Inst , vol.90 , pp. 1361-1370
- Paik, S.¹ Bryant, J.² Park, C.³ Fisher, B.⁴ Tan-Chiu, E.⁵ Hyams, D.⁶

5
- 0026625217
- Prognostic importance of c-erbB-2 expression in breast cancer
- (2001) J Clin Oncol , vol.10 , pp. 1049-1056
- Gusterson, B.A.¹ Gelber, R.D.² Goldhirsch, A.³ Price, J.⁴ Save-Soderborgh, J.⁵ Anbazhagan, R.⁶

6
- 0035421454
- Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer
- (2001) J Natl Cancer Inst , vol.93 , pp. 1141-1146
- Simon, R.¹ Nocito, A.² Hubscher, T.³ Bucher, C.⁴ Torhorst, J.⁵ Schraml, P.⁶

7
- 0001875348
- HER-2/neu/erbB-2 status by immunohistochemistry and FISH: Clonality and progression with recurrence and metastases
- [abstract]
- (2000) Breast Cancer Res Treat , vol.64 , pp. 55
- Edgerton, S.E.¹ Merkel, D.² Moore, D.H.³ Thor, A.D.⁴

8
- 0035873962
- Discrepancies in clinical laboratory testing of eligibility for tratuzumab therapy: Apparent immunohistochemical false-positives do not get the message
- (2001) J Clin Oncol , vol.19 , pp. 2714-2721
- Tubbs, R.R.¹ Pettay, J.D.² Roch, P.C.³ Stoler, M.H.⁴ Jenkins, R.B.⁵ Grogan, T.M.⁶

9
- 0033055699
- Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
- (1999) J Clin Oncol , vol.17 , pp. 1974-1982
- Jacobs, T.W.¹ Gown, A.M.² Yaziji, H.³ Barnes, M.J.⁴ Schnitt, S.J.⁵

10
- 0009941731
- Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999
- (2000) Arch Pathol Lab Med , vol.124 , pp. 966-978
- Fitzgibbons, P.L.¹ Page, D.L.² Weaver, D.³ Thor, A.D.⁴ Allred, D.C.⁵ Clark, G.M.⁶

11
- 0034900183
- Evaluation of the Food and Drug Administration-approved scoring and test system of her-2 protein expression in breast cancer
- (2001) Clin Cancer Res , vol.7 , pp. 1669-1675
- Birner, P.¹ Oberhuber, G.² Stani, J.³ Reithofer, C.⁴ Samonigg, H.⁵ Hausmaninger, H.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.